Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Abstract Background: The addition of rituximab (R) to salvage chemotherapy has been shown to improve response rates and proportion of patients subsequently transplanted with Aggressive CD 20+ Non-Hodgkin Lymphoma who were previously R naïve. It is unknown if this benefit would be seen in the era of patients requiring ASCT who had previously been treated with R + chemotherapy.